Squarepoint
MLYS icon

Squarepoint’s Mineralys Therapeutics MLYS Stock Holding History

Squarepoint’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.33M Sell
86,327
-19,164
-18% -$526K ﹤0.01% 2226
2026
Q1 		$2.86M Sell
105,491
-141,313
-57% -$4.14M ﹤0.01% 1923
2025
Q4 		$8.96M Buy
246,804
+203,791
+474% +$8.17M 0.01% 1131
2025
Q3 		$1.63M Buy
43,013
+31,498
+274% +$681K ﹤0.01% 2268
2025
Q2 		$156K Buy
+11,515
New +$167K ﹤0.01% 4054
2024
Q4 		– Sell
-20,505
Closed -$248K – 5333
2024
Q3 		$248K Buy
+20,505
New +$248K ﹤0.01% 3570

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Squarepoint's MLYS Position: Q2 2026 in Review

Squarepoint reduced its Mineralys Therapeutics (MLYS) stake by 18% in Q2 2026, selling an estimated $526K and leaving 86,327 shares worth $2.33M. The position accounts for ﹤0.01% of the portfolio, ranked #2226.

Squarepoint first reported a position in MLYS in Q3 2024 and has held it in 6 quarters since. The position peaked at $8.96M in Q4 2025. 224 funds tracked by Wall St. Rank hold MLYS as of Q2 2026.

  • Squarepoint held 86,327 shares of Mineralys Therapeutics worth $2.33M as of Q2 2026.
  • Squarepoint sold 19,164 Mineralys Therapeutics shares in Q2 2026, an estimated $526K.
  • Mineralys Therapeutics made up ﹤0.01% of Squarepoint's portfolio in Q2 2026, its #2226 holding.
  • Squarepoint first reported a position in Mineralys Therapeutics in Q3 2024 and has held it in 6 quarters since.
  • Squarepoint's Mineralys Therapeutics position peaked at $8.96M in Q4 2025.
  • 224 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.